ISPOR - Looking Beyond Survival Data in Oncology Reimbursement Decisions

vos-headline-type-email-header-062620

vos_heorarticles

HEOR Articles

Looking Beyond Survival Data: How Should We Assess Innovation in Oncology Reimbursement Decision Making

ISSUE HIGHLIGHTS

vos_heorarticles

HEOR Articles

Looking Beyond Survival Data: Do Alternative Trial Endpoints Require Alternative Pricing and Payment Models?

Cover_GSK supplement_472x676

VOL. 9, NO. 5, S1

July 2023

DOWNLOAD ISSUE

COLUMNS

Latest News

New Study Sheds Light on QALY and Disability Debate

Sep 28, 2026

HEOR Ambassadors Microsite 150x200

ISPOR Launches New HEOR Ambassadors Website

Sep 22, 2026

Decision Aids Increasingly Use Quantitative Preference Activities to Support Patients’ Clinical Decisions. But Are They Asking the Right Questions?

Aug 18, 2026

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now